Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. EC Healthcare
  6. News
  7. Summary
    2138   KYG3037S1021

EC HEALTHCARE

(2138)
  Report
Delayed Hong Kong Stock Exchange  -  08:35 2022-12-05 pm EST
6.250 HKD   +1.46%
11/24EC Healthcare's April-September Profit Falls on Higher Expenses
MT
11/24EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly Driven by Medical Services
AQ
11/23EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 20 January 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance in the Future Development of the Group

09/09/2022 | 04:59am EST

HONG KONG, Sept 9, 2022 - (ACN Newswire) - - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that on 7 September 2022, the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further acquired a total of 170,000 shares of the Company on the open market for approximately HK$854,800 at an average price of HK$5.0282 per share. Prior to this transaction, Mr. Tang had already increased his shareholding in the Company earlier this month on 1 September 2022, acquiring a total of 107,000 shares at an average price of $5.4905 per share. After the transaction, Mr. Tang holds an aggregate of 722,204,610 shares in the Company, increasing his equity stake from 61.27% to 61.29%.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "In spite of the current economic climate, we are confident that the medical market will remain resilient and that long-term public-private healthcare partnerships will continue to drive up investment in Hong Kong's private healthcare sector. Reaping the benefits from its ongoing investments in elevating healthcare service offerings, the Group exemplified solid business recovery by delivering first-quarter sales volume of no less than HK$860 million for the financial year that concluded on March 31, 2023. Management is still nevertheless upbeat about the Group's business success going forward. In order to continue enhancing EC Healthcare's enclosed healthcare ecosystem, the Group will go forward with its close collaboration with the major players in the technology, telecommunications, insurance, property, and pharmaceutical industries."

About EC Healthcare

EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre EC DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021

Copyright 2022 ACN Newswire . All rights reserved.

© Japan Corporate News, source JCN Press Releases

All news about EC HEALTHCARE
11/24EC Healthcare's April-September Profit Falls on Higher Expenses
MT
11/24EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly D..
AQ
11/23EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Pa..
CI
11/23EC Healthcare Reports Earnings Results for the Half Year Ended September 30, 2022
CI
11/11EC Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2022
CI
10/16EC Healthcare Expects Sales Volume for Six Months through September to Jump 17%
MT
10/16EC Healthcare expects a record-high semi-annual sales volume in first half of FY23 of n..
AQ
10/03Team Expert Buys 7.5% Stake in EC Healthcare Unit; EC Healthcare Shares Fall 4%
MT
10/03EC Healthcare Unit Buys 60% Stake in Pioneer Evolution for $4.6 Million; Shares Drop 4%
MT
10/02EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong
AQ
More news
Financials
Sales 2023 3 722 M 479 M 479 M
Net income 2023 216 M 27,8 M 27,8 M
Net Debt 2023 - - -
P/E ratio 2023 33,3x
Yield 2023 2,02%
Capitalization 7 276 M 937 M 937 M
Capi. / Sales 2023 1,95x
Capi. / Sales 2024 1,60x
Nbr of Employees 2 557
Free-Float 38,8%
Chart EC HEALTHCARE
Duration : Period :
EC Healthcare Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EC HEALTHCARE
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 6,16 HKD
Average target price 7,51 HKD
Spread / Average Target 21,9%
EPS Revisions
Managers and Directors
Lyn Wade Lu Co-Chief Executive Officer & Executive Director
Chi Fai Tang Chairman & Co-Chief Executive Officer
Heung Wing Lee Finance Director
Kun Shing Luk Non-Executive Director & Chief Information Officer
Ka Ki Wong Executive Director & Chief Investment Officer
Sector and Competitors